Cost of care in a randomised trial of early hospital discharge after surgery for breast cancer

1998 ◽  
Vol 34 (13) ◽  
pp. 2015-2020 ◽  
Author(s):  
J Bonnema ◽  
A.M.E.A van Wersch ◽  
A.N van Geel ◽  
J.F.A Pruyn ◽  
P.I.M Schmitz ◽  
...  
1997 ◽  
Vol 33 ◽  
pp. S2-S3
Author(s):  
J Bonnema ◽  
AMEA van Wersch ◽  
AN van Geel ◽  
JFA Pruyn ◽  
PIM Schmitz ◽  
...  

2021 ◽  
pp. 026921552110407
Author(s):  
Braden Te Ao ◽  
Matire Harwood ◽  
Vivian Fu ◽  
Mark Weatherall ◽  
Kathryn McPherson ◽  
...  

Objective: To undertake an economic analysis of the Take Charge intervention as part of the Taking Charge after Stroke (TaCAS) study. Design: An open, parallel-group, randomised trial comparing active and control interventions with blinded outcome assessment Setting: Community. Participants: Adults ( n = 400) discharged to community, non-institutional living following acute stroke. Interventions: The Take Charge intervention, a strengths based, self-directed rehabilitation intervention, in two doses (one or two sessions), and a control intervention (no Take Charge sessions). Measures: The cost per quality-adjusted life year (QALY) saved for the period between randomisation (always post hospital discharge) and 12 months following acute stroke. QALYs were calculated from the EuroQol-5D-5L. Costs of stroke-related and non-health care were obtained by questionnaire, hospital records and the New Zealand Ministry of Health. Results: One-year post hospital discharge cost of care was mean (95% CI) $US4706 (3758–6014) for the Take Charge intervention group and $6118 (4350–8005) for control, mean (95% CI) difference $ −1412 (−3553 to +729). Health utility scores were mean (95% CI) 0.75 (0.73–0.77) for Take Charge and 0.71 (0.67–0.75) for control, mean (95% CI) difference 0.04 (0.0–0.08). Cost per QALY gained for the Take Charge intervention was $US −35,296 (=£ −25,524, € −30,019). Sensitivity analyses confirm Take Charge is cost-effective, even at a very low willingness-to-pay threshold. With a threshold of $US5000 per QALY, the probability that Take Charge is cost-effective is 99%. Conclusion: Take Charge is cost-effective and probably cost saving.


2011 ◽  
Vol 103 (8) ◽  
pp. 754-756 ◽  
Author(s):  
Vijay Naraynsingh ◽  
Rakesh Rambally ◽  
Ravi Maharaj ◽  
Dilip Dan ◽  
Seetharaman Hariharan

Breast Care ◽  
2010 ◽  
Vol 5 (2) ◽  
pp. 97-101 ◽  
Author(s):  
Laurence M. Almond ◽  
Laura Khodaverdi ◽  
Belindra Kumar ◽  
Eamonn C. Coveney

2017 ◽  
Vol 2 (3) ◽  
pp. 383
Author(s):  
Ni Putu Wintariani ◽  
Ni Made Okadwicandra ◽  
Abdul Khodir Jaelani

<p><em>Breast cancer is the first sequence of most attacking women in Indonesia. The high cost of care and old services is a major problem in the prevention of breast cancer. This study aims to determine the relationship between the total cost of the Sanglah Denpasar hospital with the chemotherapy regimen of breast cancer of JKN patients at Sanglah Hospital Denpasar. Test homogeneity using Levene test method. Test normality using Kolmogorov-Smirnov. One way ANOVA test results showed a significant relationship between chemotherapy therapy regimen (FAC, FAC + PAXUS, FEC, AC, AC + PAXUS) with total real cost in breast cancer chemotherapy patients (p = 0.001). The total rill cost was greater in the group receiving FAC + PAXUS, FEC, and AC + PAXUS regimens than the group receiving FAC and AC therapy regimens. This can be caused by a large pharmaceutical cost component in the FAC + PAXUS, FEC, and AC + PAXUS groups. Pharmaceutical costs account for 76.84-85.80% of the total real cost of breast cancer patients receiving chemotherapy. More drug combination factors can lead to higher total rill costs in patients receiving FAC + PAXUS, FEC, and AC + PAXUS.</em></p>


Sign in / Sign up

Export Citation Format

Share Document